Table 5.
Body mass index, insulin resistance and homocysteine in polycystic ovary syndrome as observed in different contemporary studies compared to the present study
| Author (year), location | Sample size and study design | Characteristic | Cases | Controls |
|---|---|---|---|---|
| Bagheri et al. (2015), Iran[35] | Case-control (52 cases, 104 controls) | Age (years) | 24.27±3.75 | 25.62±4.32 |
| BMI (kg/m2) | 25.80±6.67* | 22.60±2.87 | ||
| Insulin (µIU/ml) | 16.62±7.45* | 12.04±4.24 | ||
| HOMA | 33.72±14.74* | 44.56±16.94 | ||
| Homocysteine (µmol/l) | 12.21±4.55 | 13.68±4.31 | ||
| Al-Gareeb et al. (2016), Iraq[36] | Case-control (101 cases, 106 controls) | Age (years) | 24.86 | 25.41 |
| BMI (kg/m2) | 60% >25* | 22.6% >25 | ||
| Homocysteine (µmol/l) | 11.5±5.41* | 8.10±1.89 | ||
| Esmaielzadeh et al. (2017), Iraq[31] | Case-control (60 cases, 20 controls) | Age (years) | 23.65±5.08 | 23.73±3.85 |
| BMI (kg/m2) | 29.95±4.91* | 26.09±4.80 | ||
| Insulin (µU/dl) | 17.80±8.02* | 11.55±6.81 | ||
| HOMA-IR | 3.91±1.86* | 2.49±1.63 | ||
| Homocysteine (µmol/l) | 11.68±2.92* | 9.31±2.92 | ||
| Saadeh et al. (2018), Iraq[37] | Case-control (154 cases, 151 controls) | Age (years) | 23.85±5.12 | 24.35±5.10 |
| BMI (kg/m2) | 26.57±5.98 | 26.23±5.82 | ||
| Homocysteine (µmol/l) | 29.03±11.80* | 14.23±5.53 | ||
| Suleiman and Sulaiman (2018), Jordan[38] | Case-control (50 cases, 40 controls) | Age (years) | 26.88±6.76 | 27.17±5.24 |
| BMI (kg/m2) | 27.17±5.24* | 24.24±3.39 | ||
| Homocysteine (µmol/l) | 17.00±4.00* | 9.00±2.15 | ||
| Present study (2020), Lucknow, India | Case-control (35 cases, 35 controls) | Age (years) | 23.94±4.45 | 23.83±4.64 |
| BMI (kg/m2) | 27.61±5.74 | 25.37±4.35 | ||
| Insulin (µU/dl) | 23.35±33.35* | 11.09±12.05 | ||
| HOMA-IR | 5.61±8.56* | 2.29±2.63 | ||
| Homocysteine (µmol/l) | 17.93±9.86* | 10.32±5.95 |
*A significant difference between cases and controls, BMI=Body mass index, HOMA-IR=Homoeostatic assessment of insulin resistance